A study to find how well VES001 works and how safe it is in participants with GRN -frontotemporal dementia (GRN-FTD) showing no symptoms
This study is testing a new medicine called VES001. It's for a condition called Frontotemporal Dementia (FTD), specifically in people who have a change in their GRN gene. This gene change means they are at risk of developing FTD in the future. The main goal of this early-stage study is to check if VES001 is safe to use and how the body handles it. It also aims to see if there are any early signs that the medicine could help in people who carry the GRN gene change but haven't yet shown any symptoms of dementia. This is a 'first-in-humans' study, which means it's one of the first times this medicine is being given to people. It's an important step to understand if VES001 could eventually become a treatment for GRN-FTD.
At a glance
What is this study about?
This research is looking into a new medicine called VES001 for a specific type of dementia known as Frontotemporal Dementia, or FTD. FTD is different from Alzheimer's disease and mainly affects parts of the brain that control personality, behaviour, and language.
Specifically, this study is focusing on FTD that is caused by a change in a gene called GRN. If someone has this GRN gene change, they have a higher chance of developing FTD later in life. What's particularly interesting about this study is that it's designed for people who have this GRN gene change but *haven't yet started showing any symptoms* of FTD. The hope is to find a way to intervene early.
This is an early-stage study, sometimes called a Phase I study. This means the researchers are mainly trying to find out if the new medicine, VES001, is safe and how the body reacts to it. They will be carefully watching for any side effects and seeing how the medicine moves through the body. At this stage, they'll also be looking for any early hints that the medicine might be effective in protecting brain cells or slowing down disease development. Your involvement could be vital in helping us understand more about this potential new treatment.
Key takeaways
- This study is testing a new medicine for a type of dementia called GRN-FTD.
- It's for people who have the GRN gene change but don't yet have FTD symptoms.
- The main aim is to check if the new medicine, VES001, is safe.
- It's an early-stage study, so the results will help guide future research.
- Participation involves regular clinic visits and health checks.
Who may be eligible?
To join this study, you would need to be an adult, aged 18 or older. The study is open to both men and women.
A very important part of joining this study is that you must have a specific genetic change in your GRN gene. This means you would have been identified as someone with a higher risk of developing Frontotemporal Dementia (FTD) in the future, but you shouldn't have any dementia symptoms right now.
There might be other health checks or requirements that a doctor involved with the study would discuss with you to make sure it's safe and right for you to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been told you have a GRN gene change?
- Do you currently NOT have symptoms of Frontotemporal Dementia (FTD)?
- Are you able to attend appointments regularly at a clinic or hospital?
What does participation involve?
If you decide to take part in this study, you would receive the new medicine, VES001, through a drip. You would have regular appointments at the study clinic or hospital. These visits would involve various tests to check your overall health and to see how your body is reacting to the medicine.
These tests might include blood samples, physical examinations, and possibly brain scans or memory tests. These are to closely monitor your safety and to see if the medicine is having any effects. The doctors and nurses will also ask you about how you are feeling and if you have any side effects.
The total length of time you would be involved in the study and how many visits you would need to make would be explained fully by the study team. It's also likely there will be follow-up calls or visits after you stop taking the medicine.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What is Frontotemporal Dementia (FTD)?
FTD is a type of dementia that mainly affects parts of the brain controlling personality, behavior, and language. It's different from Alzheimer's disease.
What does 'GRN-FTD' mean?
It means Frontotemporal Dementia specifically caused by a change in a particular gene called GRN. If you have this gene change, you are at a higher risk of developing FTD.
Why is the study for people with no symptoms?
The researchers want to see if the new medicine can help before symptoms start, possibly to protect the brain and prevent or slow down the disease's development.
What is a 'Phase I' study?
This is an early stage of testing a new medicine in people. The main goals are to check if it's safe and how the body handles it.
Will I get paid to participate?
Many studies cover travel expenses and provide some compensation for your time. The study team will give you all the details about this.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.